From: Friday, 3 September 2021 3:50 PM Sent: Bell, Simon; Channing, Darrell To: Exemptions Cc: Medicines Australia-ACCC Authorisation AA1000486 - fortnightly report 21 August 2021 Subject: to 3 September 2021 Dear Simon/Darrell, In relation to the ACCC Authorisation AA1000486 (24 September 2020) and, specifically, in accordance with the Conditions of that Authorisation at paragraph 5.12, Medicines Australia provides the following fortnightly report on activities related to the Proposed Conduct. In the period of 21 August 2021 to 3 September 2021, no meetings or discussions of the Medicines Australia/Generic and Biosimilar Medicines Association Working Group occurred and no decisions were made that fall under the Proposed Conduct. Medicines Australia's next fortnightly update will cover the period of 4 September 2021 to 17 September 2021. Additional updates will be provided to the ACCC as required and in accordance with Medicines Australia's obligations under the authorisation. We also consent to this nil report being published on the public register, with the appropriate privacy redactions. MA submits the following information to the ACCC, to accompany the above report, in the interest of transparency and in accordance with the intent of the authorisation granted to MA on 20 September 2020. MA requests this information is excluded from the public register,

This response was drafted in consultation with Association.

CEO of Generic and Biosimilar Medicines

Yours sincerely,

Senior Executive Assistant Medicines Australia

17 Denison Street Deakin ACT 2600 Australia

Telephone:

Email:

Web: https://medicinesaustralia.com.au













Please consider the environment before printing this email message